Top 50 Ai Diagnostics in Europe

DoMore Diagnostics develops artificial intelligence-based diagnostic technology that accurately predicts cancer progression and prognosis. This approach addresses the lack of objective methods in cancer diagnostics, enabling personalized treatment plans and improving patient outcomes.

Mindpeak develops AI-based diagnostic software that automates the detection, quantification, and classification of cancer biomarkers in histological tissue samples. This technology enhances the efficiency and accuracy of clinical pathology, enabling pathologists to focus on complex cases while reducing the time required for routine analyses.

LightHearted AI develops a laser-based diagnostics device that utilizes advanced AI to detect heart conditions by acquiring biomarkers from a distance. This contactless technology provides rapid and accurate diagnostic reports, making heart disease detection more accessible and affordable.

The startup has developed a digital diagnostics platform that utilizes artificial intelligence for genetic analysis and clinical decision support, enhancing the traceability and interoperability of bioinformatics data. This technology enables researchers and clinicians to efficiently access and reuse critical information, thereby expediting the diagnosis process for various diseases.

Hema.to utilizes AI-driven algorithms to automate blood cancer detection from flow cytometry data, providing rapid and reproducible diagnostic recommendations. This technology addresses the challenges of subjective analysis and staffing shortages in clinical cytometry labs, enhancing diagnostic throughput and accuracy.

The startup develops a medical analysis platform that integrates artificial intelligence with computational pathology to enhance diagnostic accuracy in cancer detection. By facilitating real-time collaboration between pathologists and AI, the platform improves decision-making in clinical diagnostics and drug development, ultimately increasing survival rates for cancer patients.

Floy® develops certified artificial intelligence to assist radiologists in identifying hard-to-detect abnormalities in medical imaging. This technology aims to enhance diagnostic accuracy and reduce the risk of misdiagnosis in conditions such as cancer, cardiovascular diseases, and dementia.

Aignostics utilizes multimodal AI and proprietary datasets to enhance precision diagnostics in pathology, enabling the identification of novel drug targets and improving the analysis of complex imaging and omics data for clinical research. Their foundation model achieves over 90% accuracy on histopathology benchmarks while significantly reducing the amount of training data required for new model development.

The startup develops artificial intelligence tools that automate the detection of abnormalities in radiological images and facilitate real-time notifications of anomalies during emergency workflows. This technology enhances diagnostic reliability and reduces operational time for physicians and medical specialists.

The startup develops digital microscopy and AI-driven image analysis platforms that enhance the accuracy and efficiency of cancer diagnostics. Its software enables diagnostic laboratories and pharmaceutical companies to manage and analyze patient cell and tissue images, improving diagnostic precision and patient outcomes while reducing operational time and clinician burnout.

dehaze integrates medical AI models into clinical workflows to enhance diagnostic accuracy and prognostic capabilities tailored to individual patient data. This approach addresses the limitations of standardized treatment guidelines by providing personalized healthcare solutions based on unique health profiles.

The startup develops artificial intelligence technology for medical image analysis, specifically targeting skin cancer diagnosis in clinical settings. By enhancing diagnostic precision, the solution improves the efficiency of care workflows and supports medical personnel in making more accurate disease assessments compared to traditional methods.

Raidium develops a radiology-augmented GPT that utilizes deep learning algorithms to analyze medical imaging data, providing a diagnosis suggestion interface that integrates AI assistance into radiologists' workflows. This technology enhances access to imaging biomarkers, enabling earlier detection and management of critical diseases such as cancer and cardiovascular conditions.

Provides AI-powered cardiovascular imaging analysis that delivers instant, precise measurements and specialist-level insights at the point of care. This technology reduces time to diagnosis, enabling earlier detection and intervention for cardiovascular diseases, even in settings without on-site expertise.

The startup develops nanotechnology-based diagnostic test kits that utilize photonics and AI for rapid and reliable bacterial classification at the point of care. These kits provide affordable diagnostics, enhancing patient care and mitigating the risks associated with antimicrobial resistance.

Develops medical-grade AI solutions for radiology, including applications like BoneView for bone trauma X-ray interpretation and ChestView for detecting urgent findings and early cancer indicators in chest imaging. These tools improve diagnostic accuracy, automate time-consuming tasks, and are used in over 2,000 health institutions across 40+ countries, processing more than 30 million patient exams annually.

Avicenna.ai develops AI solutions for emergency radiology, focusing on the automated detection of critical conditions such as intracranial hemorrhage and large vessel occlusion in CT scans. By reducing interpretation time and prioritizing urgent cases, their technology enhances diagnostic accuracy and improves patient outcomes in high-stakes medical environments.

Panakeia utilizes AI-driven multi-omics molecular analysis to extract biomarker information directly from H&E-stained tissue images, significantly reducing the time and cost associated with cancer diagnosis. This technology eliminates the need for multiple physical tests, providing reliable results in minutes instead of days or weeks.

Oxford Immune Algorithmics develops Algocyte®, a precision diagnostics platform that utilizes Artificial General Intelligence to create digital blood-based twins for remote health monitoring. This technology addresses the challenges of chronic disease management and early detection by providing personalized risk assessments and predictive insights based on individual health data.

The startup has developed an AI-driven chest X-ray radiology suite that automates the diagnosis and reporting of healthy patients by identifying normal X-ray images and generating preliminary reports only for cases with high confidence in abnormalities. This technology enables radiologists to concentrate their efforts on cases that require further examination, improving diagnostic efficiency and patient care.

Powerful Medical offers the PMcardio platform, which utilizes AI algorithms to interpret 12-lead ECGs and deliver accurate cardiovascular diagnostics in under five seconds. This technology enhances clinical decision-making by providing standardized reports and facilitating care coordination among healthcare professionals, ultimately improving patient outcomes in cardiovascular care.

Deep Breathe combines lung ultrasound with artificial intelligence to provide portable and autonomous diagnostics for respiratory diseases. This technology enables real-time detection of critical conditions like pneumothorax, improving diagnostic accuracy and patient outcomes in various clinical settings.

C the Signs offers an AI-powered platform that evaluates more than 1,000 clinical and laboratory data points to produce cancer risk scores and actionable recommendations in under 60 seconds. The solution integrates with EHR systems via HL7/FHIR, providing clinician dashboards and patient portals that enable rapid referral and shared decision‑making while maintaining 99% sensitivity for cancer detection.

This healthcare technology firm utilizes AI and data analytics to provide actionable insights from patient data, enabling precise diagnostics and tailored treatment plans. By integrating these capabilities into clinical workflows, the platform enhances decision-making and improves the quality of patient care.

The startup develops an artificial intelligence-based healthcare technology that utilizes MRI and multi-omics biomarkers to enhance cancer detection and diagnosis. By providing accurate and cost-effective reporting tools, the technology enables clinicians to improve the speed and accessibility of cancer screening.

Previeni is developing a portable, AI-powered imaging system that detects medical conditions such as edema, cancer, and hemorrhagic events before symptoms appear. This technology aims to reduce late diagnoses and potentially lower patient mortality rates in emergency settings by over 50%.

Dxcover is developing a multi-cancer diagnostic platform that utilizes liquid biopsy and an AI engine for the early detection of brain tumors. This technology aims to improve patient survival rates by enabling earlier diagnosis, addressing the critical challenge of late-stage cancer detection.

The startup develops an artificial intelligence-powered diagnostic software that utilizes video and sensor data, combined with computer vision and machine learning, to monitor and analyze epilepsy seizures. This platform provides neurologists and patients with critical insights into seizure patterns, enhancing treatment decisions and patient care.

INTA Systems develops the NanoAnalyzer, a portable biosensor that utilizes lab-on-a-chip technology and AI algorithms to detect up to six biological analytes from a single drop of blood. This system provides rapid and accurate diagnostics for medical, environmental, and industrial applications, enhancing accessibility to critical testing in various settings.

The startup develops AI-augmented biosensing solutions that analyze unique disease biomarkers to enhance diagnostic accuracy. This technology aims to reduce the risk of misdiagnosis and improve patient outcomes by providing timely and precise health insights.

Ophiomics develops in vitro diagnostic devices that utilize artificial intelligence and genomics to enhance early cancer detection and optimize treatment selection. Their technology integrates machine learning algorithms with clinical and biomarker data to improve decision-making for clinicians, ultimately aiming to enhance patient outcomes in oncology.

This startup provides AI-powered software that assists medical professionals with diagnosis and treatment planning. It analyzes patient data and discharge letters to offer individualized diagnostic suggestions and therapy recommendations, helping doctors predict treatment courses.

AiMorphous Health is developing an AI-powered blood diagnostic system that utilizes machine learning algorithms to identify early biomarkers of thrombosis, a leading cause of heart attacks and strokes. This technology aims to enable timely detection and intervention, potentially preventing over 80% of thrombosis cases that currently go undiagnosed.

The startup has developed a cloud-based health diagnostics platform that utilizes AI-enhanced Nuclear Magnetic Resonance to convert blood samples into digital representations, creating a digital twin of patients. This technology provides affordable health testing for preventative care and precision medicine by delivering metabolic insights derived from blood metabolism measurements.

Fleming is a healthcare app that utilizes artificial intelligence to provide preliminary medical diagnoses through a symptom checker and a secure medical database, ensuring reliable information for users. The platform addresses the challenges of misinformation and self-diagnosis by guiding patients towards trusted medical insights and facilitating efficient communication of health data for medical professionals.

GeneSys Bio offers a portable, battery‑operated molecular diagnostics system that automates nucleic‑acid extraction, rapid PCR or isothermal amplification, and AI‑driven data interpretation to deliver results in under 60 minutes. The modular cartridge platform supports multiplex detection of bacteria, viruses, fungi and antibiotic‑resistance genes across human, animal and environmental samples, with secure cloud reporting for integration with laboratory information systems. It is designed for point‑of‑care clinical labs, veterinary diagnostics and field epidemiology teams that need fast, laboratory‑grade testing without centralized facilities.

Presymptom Health develops AI-based diagnostic blood tests that provide rapid and accurate detection of infections, including sepsis, with a ruling-out accuracy of 95-99%. Their technology addresses the critical need for timely infection diagnosis, reducing unnecessary hospital admissions and combating antimicrobial resistance.

Cancilico develops AI-powered diagnostic solutions that utilize image analysis to enhance the accuracy and efficiency of diagnosing hematological cancers. The company provides AI-driven services for medical research, addressing the need for improved diagnostic precision in the healthcare industry.

HippocratesAI is an AI-powered medical assistant that utilizes advanced algorithms for accurate diagnosis and intelligent triage, enabling healthcare professionals to streamline patient assessment and prioritize urgent cases. The platform reduces unnecessary emergency room visits and lowers out-of-pocket expenses for patients while enhancing diagnostic capabilities and access to medical information, particularly in developing countries.

Vital Beats employs AI algorithms to analyze data from implanted cardiac devices, delivering real-time diagnostics and tailored treatment plans for patients with cardiac conditions. This technology enhances patient monitoring and facilitates timely medical interventions, ultimately improving clinical outcomes.

Birdia offers an AI-powered platform that analyzes aerial imagery to provide precise diagnostics for roofing structures. It automatically detects damage, material anomalies, and structural measurements, enabling remote assessments and optimized intervention planning.

medicalvalues offers an AI-powered platform that streamlines medical diagnostics for laboratories and clinics. It provides pre-built AI models and tools to optimize diagnostic workflows, standardize data, and improve patient care.

CheckApp is an AI-powered health diagnostics platform that utilizes image analysis of facial and tongue photos to identify early signs of potential health issues. The platform delivers personalized health reports with actionable recommendations, enabling users to monitor their well-being and make informed health decisions.

AINOSTICS develops AI algorithms and MRI measurement techniques to identify early biological signs of neurological disorders, such as Alzheimer's disease and multiple sclerosis. Their platform enhances clinical diagnosis and treatment planning by providing automated, data-driven insights from multi-modal imaging and non-imaging data.

Nine Diagnostics develops AI-enhanced nanosensor technology to create holistic patient profiles by analyzing personal health data, demographics, and social determinants of health. This approach enables the rapid detection of health abnormalities and treatment effectiveness, addressing the critical need for timely and effective cancer therapies.

Behold.ai offers the red dot® platform, an AI-driven diagnostic tool for CT and X-Ray imaging that rapidly identifies conditions such as lung cancer and stroke. This technology significantly reduces diagnostic wait times, enabling healthcare providers to triage patients within seconds instead of days, thereby improving patient outcomes and operational efficiency.

Humanbytes offers a curated portfolio of AI solutions to enhance diagnostic capabilities and streamline clinical workflows in healthcare. Their platform integrates best-in-class AI technologies for specialties like radiology, neurology, and digital pathology, simplifying AI deployment for hospitals and clinics.

Moonlight AI develops an artificial intelligence diagnostics platform that utilizes computer vision to identify genomic aberrations from blood or bone marrow smears, enabling hematologists to make informed treatment decisions for cancer patients. This approach democratizes access to essential genomic information, significantly reducing the time and cost associated with traditional Next-Generation Sequencing methods.

The startup provides transparent AI technology that enhances tissue-based diagnostics and prognostics in computational pathology. By integrating with existing workflows, it improves disease treatment efficiency in clinical and pharmaceutical settings, enabling personalized medicine through effective AI utilization.

PAICON utilizes a centralized data lake to aggregate and harmonize diverse cancer datasets, enabling the development of AI algorithms for accurate and early diagnostics. By providing access to real-world data and advanced analytics, PAICON enhances decision-making in oncology, improving patient outcomes through personalized medicine.